Company intelligence / Profile preview

Amtix Bio

Ownership: Private
Development stage: Other

Overview

Amtix Bio is developing innovative first-in-class small molecule drugs targeting microbial virulence factors and related inflammatory pathways for infectious and inflammatory diseases. Its lead asset, ATB1651, is in Phase 2 clinical trials for onychomycosis. Other pipeline programs are in preclinical stages targeting bacterial infections, aspergillosis, inflammatory bowel disease, and infectious lung disorders[1][2][4].

Therapeutic areas: GastroenterologyInfectious Diseases
Modalities: Small molecule
Industry: Biotech

Drug pipeline

4 assets

ATB1651

3 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on Amtix Bio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Amtix Bio.

Explore the full profile